TP53BP1 and neoplasm: We also found that a patient-derived tumour ex vivo culture with low BRCA1 and 53BP1 expression was resistant to olaparib or carboplatin but sensitive to ART558 (Fig. 3m, Supplementary Fig. 3k,l).